Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
1.
Tuberculosis and Respiratory Diseases ; : 231-233, 2012.
Artículo en Inglés | WPRIM | ID: wpr-148474

RESUMEN

Tadalafil is a phosphodiesterase-5 inhibitor (PDE5I), which is widely used to treat erectile dysfunction. Although PDE5Is have excellent safety profiles, and most of the side effects are mild, rare serious adverse events have been reported in association with PDE5Is. Thrombosis is one of those events, and a few previous reports have suggested the association of PDE5Is with thrombosis. We report the case of a 61-year-old male who developed pulmonary embolism combined with pulmonary infarction directly after taking tadalafil. Both the patient and the physician suspected tadalafil as the culprit drug, as the patient was in an otherwise healthy condition. However, after extensive evaluation, we noticed that factor VIII levels were elevated. Prior reports suggesting the association between thrombosis and PDEIs either lack complete information on coagulation factors, or show inconsistencies in their results. Physicians should operate caution prior to accepting the diagnosis of adverse drug reaction.


Asunto(s)
Humanos , Masculino , Persona de Mediana Edad , Factores de Coagulación Sanguínea , Carbolinas , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 5 , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Disfunción Eréctil , Factor VIII , Inhibidores de Fosfodiesterasa 5 , Embolia Pulmonar , Infarto Pulmonar , Trombosis , Tadalafilo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA